Korean Medication Algorithm for Bipolar Disorder 2018: Manic Episode
- Author:
Young Sup WOO
1
;
Won Myong BAHK
;
Bo Hyun YOON
;
Duk In JON
;
Jeong Seok SEO
;
Won KIM
;
Jung Goo LEE
;
Jong Hyun JEONG
;
Moon Doo KIM
;
InKi SOHN
;
Se Hoon SHIM
;
Hoo Rim SONG
;
Kyung Joon MIN
Author Information
1. Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Bipolar disorder;
Manic episode;
Pharmacotherapy;
KMAP-BP 2018
- MeSH:
Advisory Committees;
Bipolar Disorder;
Drug Therapy;
Humans
- From:
Mood and Emotion
2018;16(1):13-24
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: We revised the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2014 to provide more timely information for the use of the information by clinicians.METHODS: We performed the survey using a questionnaire for the treatment of manic or hypomanic episode in the participants. There were sixty-one members of the review committee who completed the survey. The executive committee analyzed the results and discussed the final production of the applicable algorithm as considering the scientific evidence.RESULTS: The combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP) was recommended as the treatment of choice (TOC), and a monotherapy with an AAP was the first-line pharmacotherapeutic strategy for the initial treatment of mania, with or without psychotic features. The MS monotherapy was the first-line choice therapy, but only for the non-psychotic mania patients. When the initial treatment failed, the TOC was a combination of a MS and an AAP in mania with or without psychotic features, and a combination of two AAPs was TOC for the psychotic mania, as well. For hypomania, the monotherapy with MS or AAP was the first-line as initial treatment, and the recommended switch to or add an AAP was recommended when the initial strategies failed.CONCLUSION: Compared with the previous version, the experts recommend more intensive interventions earlier when initial treatment failed to respond to a recommended monotherapy.
